Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
Researchers sought to determine how and which factors contribute to healthcare utilization by patients with AML at the end of life.
Comparison of results from 2 phase 3 studies of combination therapies are presented at ASH 2020.
There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.
Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.
Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.